证券代码：002412 证券简称：汉森制药 公告编号：2025-014 湖南汉森制药股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示 1．本次股东大会无否决、修改或新增议案的情况。 2．本次股东大会无变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间 （1）现场会议时间：2025 年 5 月 21 日（星期三）14∶30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 21 日 9:15—9:25、9:30—11:30 和 13:00—15:00；通过深圳证券交 易所互联网投票系统进行网络投票的具体时间为 2025 年 5 月 21 日 9:15 至 2025 年 5 月 21 日 15:00 的任意时间。 5．会议主持人：公司董事长兼总裁刘正清先生 6．本次股东大会的召集、召开程序符合《公司法》《上市公司股东会规则》等 法律、法规、规范性文件以及《公司章程》的规定。 （二）股东出席会议情况 出席本次股东大会的股东及股东授 ...

湖南启元律师事务所 HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号 世茂环球金融中心 63 层 410000 Tel：(0731) 8295 3778 Fax：(0731) 8295 3779 http://www.qiyuan.com 湖南启元律师事务所 关于湖南汉森制药股份有限公司 2024 年年度股东大会的 法律意见书 致：湖南汉森制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南汉森制药股份有限公司 （以下简称"公司"）的委托，指派本所律师出席公司 2024 年年度股东大会（以 下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员及 召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本 法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》等我国现行 法律、法规、规范性文件以及《湖南汉森制药股份有限公司章程》（以下简称"《公 司章程》"）的有关规定出具本法律意见书。 本所律师声明如下： （一）本所律师根据本法律意见书出具日以前 ...

Core Insights - The company achieved a total revenue of 1.004 billion yuan in 2024, marking a year-on-year growth of 5.12% [1][4] - Net profit attributable to shareholders was 220 million yuan, with a year-on-year increase of 7.43%, but the growth rate significantly slowed compared to 2023 [1][4] - The growth rate of non-recurring net profit dropped from 22.97% in 2023 to 2.89% in 2024, indicating a weakening in the company's profitability excluding non-recurring items [1][4] Revenue and Profit Performance - The company's total revenue surpassed 1 billion yuan for the first time, driven by the sustained promotion of core products and optimization of sales channels [4] - However, the slowdown in net profit growth raises concerns, with a decline from 22.31% in 2023 to 7.43% in 2024 [4] - Rolling quarter-on-quarter data shows total revenue grew by 4.05%, while net profit and non-recurring net profit experienced negative growth of -2.56% and -6.14%, respectively [4] Core Product Performance - Core products such as Si Mo Tang oral liquid and Suo Quan capsules performed well in the market, with Si Mo Tang being a unique product under the national medical insurance directory [4] - The company secured selection in multiple centralized procurement projects, reinforcing its market position [4] - Other products like Suo Quan capsules and Tian Ma Xing Nao capsules have also entered various county-level medical community directories, indicating successful market penetration [4] Market Challenges - The company faces significant market pressure due to deepening medical insurance reforms and the expansion of centralized procurement, which may lead to price reductions and profit margin compression [5] - Ongoing medical anti-corruption efforts impose higher compliance requirements on the company's marketing strategies, making it crucial to maintain competitiveness while adhering to regulations [5] R&D Investment Trends - R&D investment decreased to 39.32 million yuan in 2024, a decline of 7.28% year-on-year, with R&D expenditure accounting for 3.91% of total revenue, down 0.53 percentage points from 2023 [6] - The reduction in R&D spending could hinder the launch of new products and upgrades of existing ones, potentially weakening market competitiveness [6] - Despite some achievements in R&D, such as obtaining registration certificates for certain products, the overall decline in investment raises concerns about future growth [6] Overall Assessment - The company maintained revenue and net profit growth in 2024, but the slowdown in growth rates and decline in R&D investment highlight challenges in adapting to market competition and policy changes [6] - Future strategies should focus on enhancing core product competitiveness, increasing R&D investment, and optimizing cost structures for sustainable development [6]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with no false records or significant omissions [2][3] - The quarterly report has not been audited [3][11] Financial Data Summary - Cash and cash equivalents decreased by 39,733,803.29 yuan, a decline of 31.04%, primarily due to the purchase of new bank wealth management products [5] - Trading financial assets increased by 85,547,723.78 yuan, a growth of 35.04%, attributed to increased purchases of bank wealth management products [5] - Contract liabilities decreased by 1,175,424.99 yuan, a decline of 43.17%, due to a reduction in payments received related to sales contracts [5] - Employee compensation payable decreased by 21,782,047.41 yuan, a decline of 54.81%, mainly due to the distribution of last year's year-end bonuses [5] - Other current liabilities increased by 19,808,881.52 yuan, a growth of 157.76%, due to an increase in endorsed bank acceptance bills [5] - Other comprehensive income decreased by 21,337,283.83 yuan, a decline of 70.07%, due to a reduction in the other comprehensive income of associates accounted for using the equity method [5] - Management expenses increased by 6,865,983.25 yuan, a growth of 56.21%, due to increased expenses for annual meetings and business hospitality [5][6] - Financial expenses decreased by 159,438.54 yuan, a decline of 38.82%, due to reduced bank loans and interest expenses [6] - Other income decreased by 1,661,762.99 yuan, a decline of 60.78%, due to a reduction in government subsidies received [6] - Investment income decreased by 49,866,535.38 yuan, a decline of 1087.13%, primarily due to a decrease in investment income from associates [6] - Net profit decreased by 47,007,509.82 yuan, a decline of 80.68%, mainly due to reduced investment income from associates [7] - Net cash flow from operating activities increased by 28,903,273.80 yuan, a growth of 140.97%, due to reduced cash payments for goods and services [7] - Net cash flow from investing activities decreased by 90,110,004.98 yuan, a decline of 6777.25%, due to increased cash payments for bank wealth management products [8] - Net cash flow from financing activities decreased by 2,192,009.64 yuan, a decline of 119.68%, due to previous year's funding received by a subsidiary [8] - The net increase in cash and cash equivalents decreased by 63,398,740.82 yuan, a decline of 267.90%, due to changes in cash flows from operating, investing, and financing activities [8]

Group 1 - The company held the sixth board meeting and the seventh supervisory board meeting on April 24, 2025, to review and approve the 2024 profit distribution plan, which will be submitted to the 2024 annual general meeting for approval [1][4]. - The audit committee found that the profit distribution plan aligns with the company's actual situation and does not harm the interests of shareholders, especially minority shareholders [1][3]. - The board of directors believes the profit distribution plan considers the company's current and future investment needs and is beneficial for the company's normal operations and healthy development [2][3]. Group 2 - The company achieved a net profit attributable to shareholders of 220,244,409.11 yuan for 2024, with the parent company reporting a net profit of 152,528,625.53 yuan [5]. - The profit distribution plan proposes not to distribute cash dividends, issue bonus shares, or increase capital from reserves, with undistributed profits carried forward to the next year [5][6]. - The decision to not distribute dividends is based on the company's development strategy and the need to maintain operational stability and risk resilience [6]. Group 3 - The company approved the use of idle self-owned funds for cash management, with a limit of up to 400 million yuan to purchase low-risk financial products or structured deposits [9][10]. - The purpose of this cash management is to enhance the efficiency of fund usage without affecting normal operations, thereby increasing returns for the company and its shareholders [9][10]. - The board and supervisory board agreed that the current financial situation is stable, and the proposed cash management will not adversely affect the company's operations [17][38]. Group 4 - The supervisory board meeting also approved the 2024 annual financial settlement report, which reflects the company's financial status and operating results accurately [28][31]. - The internal control evaluation report for 2024 was approved, indicating no significant deficiencies in the internal control system [37]. - The company will implement the cash management decision within a 12-month period from the approval date [13].

资产评估报告 北京亚超评报字（2025）第 A110 号 北 京 亚 超 资 产 评 估 有 限 公 司 BeijingYaChaoAsset s AppraisalCo.,Ltd. 本资产评估报告依据中国资产评估准则编制 湖南汉森制药股份有限公司因编制财务报告需要 进行商誉减值测试涉及云南永孜堂制药有限公司、云 南康佰佳医药有限公司 资产组（含商誉）可收回金额 (共 2 册，第 1 册) 二零二五年四月十八日 公司地址：北京市海淀区复兴路 47 号天行建商务大厦 20 层 2202 邮编：100036 电话：（010）51716863 | 资产评估报告声明 1 | | | | --- | --- | --- | | 资产评估报告摘要 | | 3 | | 资产评估报告正文 | | 7 | | 一、 | 绪言 | 7 | | 二、 | 委托人、 CGU | 产权持有单位和资产评估委托合同约定的其他资产评估报告使用人 | | 概况 | 8 | | | 三、 | 评估目的 | 22 | | 四、 | 评估对象和评估范围 | 23 | | 五、 | 价值类型 | 41 | | 六、 | 评估基准日 | 42 | | ...

关于湖南汉森制药股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表的 专项审核报告 众环专字(2025)1100174号 关于湖南汉森制药股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 （此页无正文，为关于湖南汉森制药股份有限公司非经营性资金占用及其他关联资金往来情 况汇总表的专项审核报告众环专字(2025)1100174号签章页） 中审众环会计师事务所（特殊普通合伙） 中国注册会计师： 众环专字(2025)1100174 号 湖南汉森制药股份有限公司全体股东： 我们接受委托，在审计了湖南汉森制药股份有限公司（以下简称"汉森制药公司"）2024 年 12 月 31 日合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及公司的现 金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇总表"）进 行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号——上市公 司资金往来、对外担保的监管要求》的规定，编制和披露汇总表、提供真实、合法、完整的 审 ...

湖南汉森制药股份有限公司 审 计 报 告 众环审字(2025) 1100108号 审 计 报 告 众环审字(2025)1100108 号 湖南汉森制药股份有限公司全体股东： 一、审计意见 我们审计了湖南汉森制药股份有限公司（以下简称"汉森制药公司"）财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并及公司 现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 汉森制药公司 2024 年 12 月 31 日合并及公司的财务状况以及 2024 年度合并及公司的经营成 果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于汉森制药公司，并履行了职业道德方面的其他责任。我们相信，我 们获取的审计证据是充分、适当的，为发表审计意见提供了基础。 三、关键审计事项 关键审计事项是我们根据职业判断，认为对本期财务报表审 ...

湖南汉森制药股份有限公司 内部控制审计报告 众环审字(2025)1100109号 湖南汉森制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了湖 南汉森制药股份有限公司（以下简称"汉森制药公司"）2024 年 12 月 31 日的财务报告内部 控制的有效性。 内部控制审计报告 众环审字(2025)1100109 号 一、汉森制药公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是汉森制药公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，湖南汉森制药股份有限公司于 2024 年 ...

2024 年度独立董事述职报告（胡高云） 本人作为湖南汉森制药股份有限公司（以下简称"公司"）的独立董事，严 格按照《公司法》《证券法》《公司章程》等规定和要求，在 2024 年度工作中 诚实、勤勉、独立地履行职责，积极出席相关会议，认真审议董事会各项议案， 充分发挥了独立董事及各专门委员会委员的作用，切实维护了公司和股东特别是 中小股东的利益，较好地发挥了独立董事作用。现将本人在 2024 年度履行独立 董事职责情况报告如下： 一、基本情况 本人胡高云，出生于 1963 年 9 月，曾任湖南省卫生学校、湖南省卫生职工 医学院教师，湖南医学专科学校教研室主任，湖南医学高等专科学校教师、药物 化学教研室主任、药学系副主任，湖南汉森医药研究有限公司总经理，中南大学 湘雅药学院教授、博士生导师，湖南省高校"创新药物研究与开发"产学研合作 示范基地主任。现任长沙晶易医药科技股份有限公司药物研究院院长，湖南安生 美药物研究院有限公司董事，湖南汉森制药股份有限公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 湖南汉森制药股份有限公司 2024 年度独立董 ...